Ozempic, Wegovy Won’t Raise Thyroid Cancer Risk, New Study Suggests

Ozempic, Wegovy and other popular drugs used to treat diabetes and obesity do not increase the risk of thyroid cancer, a new study suggests.

While previous investigations have raised concerns about a possible link between drugs known as GLP-1 analogues and thyroid tumors,

researchers say they found no association after an extensive investigation.

The study included about 145,000 adults receiving GLP-1 treatment, mainly with semaglutide, and 290,000 being treated with another diabetes drug.

Thyroid cancer rates in the two groups were compared for just under four years, and no increased risk with GLP-1 analogues was identified.

The results remained the same even after comparison with a third diabetes medication.

The lead researcher says, "Our study covers a broad group of patients and provides strong support that GLP-1 analogues are not associated with an increased risk of thyroid cancer.”